Beacon Therapeutics said its investigational gene therapy for X-linked retinitis pigmentosa (XLRP) met its primary endpoint in a pivotal trial, with patients showing improved visual acuity. XLRP is a rare inherited condition that causes progressive vision loss and can lead to blindness.
The company framed the result as a step toward regulatory submission, with an FDA approval request now on the horizon. According to the report, the outcome is especially notable because larger pharmaceutical companies have had difficulty finding success in this particular form of vision loss, leaving room for a smaller biotech to lead.
The trial data were described as positive, though the source did not provide detailed safety or durability figures. Beacon now moves forward with plans to seek regulatory approval for the therapy.